论文部分内容阅读
目的:探讨阿托伐他汀和百令胶囊联用对原发性肾病综合征患者肾功能的影响。方法:选取2013年5月—2015年11月间收治的原发性肾病综合征患者68例,将其分为对照组和观察组,每组34例;对照组患者给予常规治疗和阿托伐他丁治疗,观察组患者在对照组治疗基础上加用百令胶囊治疗,比较两组患者治疗后的总有效率和肾功能指标。结果:观察组患者治疗后的总有效率为94.12%高于对照组(χ2=8.64,P<0.05);观察组的凝血酶原时间(PT)为(11.03±1.56)s显著低于对照组(t=12.57,P<0.05);24 h尿蛋白定量(Pr)、血尿素氮(BUN)、胆固醇(TC)分别为(1.86±0.32)g、(7.32±0.53)mmol/L和(8.18±1.64)mmol/L均高于对照组(t=12.48,15.23和13.75,P<0.05);两组患者用药期间均未出现明显的不良反应症状。结论:采用阿托伐他丁和百令胶囊联合治疗原发性肾病综合征患者的疗效较为显著,显著改善患者的微炎症状态,减轻蛋白尿,有利于延缓肾功能的减退,疗效较为确切。
Objective: To investigate the effects of combination of atorvastatin and Bailing on renal function in patients with primary nephrotic syndrome. Methods: Sixty-eight patients with primary nephrotic syndrome who were admitted between May 2013 and November 2015 were selected and divided into control group and observation group with 34 cases in each group. Patients in the control group were treated with routine treatment and atorvastatin In the treatment group, patients in the observation group were treated with Bailing capsule on the basis of the control group, and the total effective rate and renal function indexes after treatment were compared between the two groups. Results: The total effective rate of the observation group after treatment was 94.12% higher than that of the control group (χ2 = 8.64, P <0.05); the prothrombin time (PT) in the observation group was (11.03 ± 1.56) s significantly lower than that of the control group (t = 12.57, P <0.05). The urinary protein levels of Pr, BUN and TC in 24 h were (1.86 ± 0.32) g, (7.32 ± 0.53) mmol / L and ± 1.64) mmol / L were higher than those in the control group (t = 12.48,15.23 and 13.75, P <0.05). No significant adverse reactions were observed in both groups during the treatment. Conclusion: The combination of atorvastatin and Bailing capsule in the treatment of patients with primary nephrotic syndrome is more effective. It can significantly improve the patients’ micro-inflammatory status and reduce proteinuria, which can delay the decline of renal function.